Benefits of endoscopic gallbladder stenting following percutaneous transhepatic gallbladder drainage.

Adverse events Cholecystitis Cystic duct Drainage Endoscopy Follow-up Gallbladder Stents

Journal

World journal of gastrointestinal surgery
ISSN: 1948-9366
Titre abrégé: World J Gastrointest Surg
Pays: United States
ID NLM: 101532473

Informations de publication

Date de publication:
27 Sep 2024
Historique:
received: 13 06 2024
revised: 10 07 2024
accepted: 05 08 2024
medline: 1 10 2024
pubmed: 1 10 2024
entrez: 1 10 2024
Statut: ppublish

Résumé

Endoscopic transpapillary gallbladder drainage is challenging because of the complexity of the procedure and high incidence of adverse events (AEs). To overcome these problems, endoscopic gallbladder stenting (EGBS) after percutaneous transhepatic gallbladder drainage (PTGBD) can be effective, as it mitigates inflammation and adhesion. To examine the benefits of EGBS after PTGBD to assess its efficacy and impact on AEs. We retrospectively analyzed data from 35 patients who underwent EGBS after PTGBD at a single center between January 2016 and December 2023. The primary outcomes were technical success and AEs, and the rate of recurrent cholecystitis was evaluated. In addition, the reasons for the failure of the procedure were identified. Among the 35 patients, the technical success rate was 77.1% and the final contrast of the cystic duct was successful in 97.1% of patients. The incidence of early AEs was relatively low (11.4%), with no instances of cystic duct perforation. The rate of recurrent cholecystitis was 3.7%, and no other biliary events were observed. EGBS after PTGBD may be significantly beneficial, with a substantial success rate and minimal AEs in both short- and long-term follow-ups.

Sections du résumé

BACKGROUND BACKGROUND
Endoscopic transpapillary gallbladder drainage is challenging because of the complexity of the procedure and high incidence of adverse events (AEs). To overcome these problems, endoscopic gallbladder stenting (EGBS) after percutaneous transhepatic gallbladder drainage (PTGBD) can be effective, as it mitigates inflammation and adhesion.
AIM OBJECTIVE
To examine the benefits of EGBS after PTGBD to assess its efficacy and impact on AEs.
METHODS METHODS
We retrospectively analyzed data from 35 patients who underwent EGBS after PTGBD at a single center between January 2016 and December 2023. The primary outcomes were technical success and AEs, and the rate of recurrent cholecystitis was evaluated. In addition, the reasons for the failure of the procedure were identified.
RESULTS RESULTS
Among the 35 patients, the technical success rate was 77.1% and the final contrast of the cystic duct was successful in 97.1% of patients. The incidence of early AEs was relatively low (11.4%), with no instances of cystic duct perforation. The rate of recurrent cholecystitis was 3.7%, and no other biliary events were observed.
CONCLUSION CONCLUSIONS
EGBS after PTGBD may be significantly beneficial, with a substantial success rate and minimal AEs in both short- and long-term follow-ups.

Identifiants

pubmed: 39351569
doi: 10.4240/wjgs.v16.i9.2902
pmc: PMC11438794
doi:

Types de publication

Journal Article

Langues

eng

Pagination

2902-2909

Informations de copyright

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Auteurs

Fumitaka Niiya (F)

Division of Gastroenterology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Yokohama 227-8501, Kanagawa, Japan.

Naoki Tamai (N)

Division of Gastroenterology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Yokohama 227-8501, Kanagawa, Japan.

Masataka Yamawaki (M)

Division of Gastroenterology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Yokohama 227-8501, Kanagawa, Japan.

Jun Noda (J)

Division of Gastroenterology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Yokohama 227-8501, Kanagawa, Japan.

Tetsushi Azami (T)

Division of Gastroenterology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Yokohama 227-8501, Kanagawa, Japan.

Yuichi Takano (Y)

Division of Gastroenterology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Yokohama 227-8501, Kanagawa, Japan. yuichitakano1028@yahoo.co.jp.

Fumiya Nishimoto (F)

Division of Gastroenterology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Yokohama 227-8501, Kanagawa, Japan.

Masatsugu Nagahama (M)

Division of Gastroenterology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Yokohama 227-8501, Kanagawa, Japan.

Classifications MeSH